Immunomedics Dodges Manufacturing Site Specifics In Quest For Cancer Breakthrough Approval
Biotech firm chooses words carefully to wind its way through site inspection findings and CMC review concerns in hopes of winning its first FDA approval for a breakthrough breast cancer treatment.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
The latest oncology development news and highlights from our US FDA Performance Tracker.
The latest drug development news and highlights from our US FDA Performance Tracker.